Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Daiichi Sankyo: Clinical Trials & FDA Approval Profile

Daiichi Sankyo (Tokyo, JP / Basking Ridge, NJ) sponsors 60 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 39 active protocols (20 recruiting now), 17 completed protocols, and 6 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.7%
Median Closed Enrollment vs National (145 pts)162 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Daiichi Sankyo
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)60
Active Pipeline (Recruiting Now)39 (20)
Completed vs Stopped Early17 / 4 (6.7%)
Median Closed Actual Enrollment162 participants
Physical Hospital Site Disclosure97.5% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals6 (5 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Daiichi Sankyo
Hospital Research SiteLocationShared Protocols
Samsung Medical CenterSeoul, Gangnam-Gu26
Asan Medical CenterSeoul22
Seoul National University HospitalSeoul21

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Daiichi Sankyo
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06172478A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsPhase IIRECRUITING
NCT06203210A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerPhase IIIRECRUITING
NCT06731478Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancPhase IIIRECRUITING
NCT06161025A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CanPhase II/IIIRECRUITING
NCT06824168Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionPhase IIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Daiichi Sankyo Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI